clinical trial · NCT07281872
Bioequivalence Study of WP205 in Healthy Participants
Wanbangde Pharmaceutical Group Co., LTD·phase1·completed·n = 20
Therapeutic Equivalency, HealthyMethylcobalamin Injection(WP205)Methylcobalamin for Injection
brief summary
This study is a single-center, randomized, open-label, two-period, two-sequence, single-dose, crossover bioequivalence trial conducted under fasting conditions in healthy adult volunteers. Participants will be randomized into two sequences (A and B). Each participant will receive a single intramuscular dose of the test or reference formulation according to the assigned sequence, with an adequate washout period between dosing. The primary objective of the study is to evaluate the bioequivalence of the two formulations.
started
Oct 29, 2025
primary completion
Nov 6, 2025
completion
Nov 21, 2025
last updated
Aug 17, 2026
official title
A Single-Center, Randomized, Open-Label, Two-Period, Two-Sequence, Single-Dose, Crossover Bioequivalence Study of Methylcobalamin Injection and Methylcobalamin for Injection in Healthy Subjects Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol